Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 6/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589268 | 0.88 | ABL1 (0.56) | ABL1ROR1CSF1R | |
| SCHEMBL16644459 | 0.84 | CSF1R (0.64) | ABL1KITFLT3DDR1BRAF | |
| SCHEMBL15510904 | 0.81 | ABL1 (0.59) | ABL1KITDDR1DDR2 | |
| SCHEMBL9610746 | 0.79 | ABL1 (0.50) | ABL1SMN1; SMN2KITFLT3BRAF | |
| SCHEMBL4104430 | 0.75 | CSF1R (0.61) | SMN1; SMN2FLT3BRAFCSF1R | |
| SCHEMBL17936026 | 0.75 | BRAF (0.54) | SMN1; SMN2FLT3BRAF | |
| SCHEMBL20922210 | 0.75 | ABL1 (0.45) | ABL1KITBRAFROR1 | |
| SCHEMBL10265618 | 0.74 | PDGFRB (0.52) | ABL1SMN1; SMN2FLT3 | |
| SCHEMBL20912688 | 0.73 | ABL1 (0.43) | ABL1KITDDR1BRAFROR1 | |
| SCHEMBL15510693 | 0.73 | ABL1 (0.87) | ABL1KITDDR1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ABL1 2649/4885SMN1; SMN2 19/4885KIT 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.